Medical Devices & Technology

Santa Clarita – November 06, 2026 -- Bioness Medical, Inc. has named Burke Rehabilitation one of 10 clinics nationwide in the inaugural 2026 Bioness Clinic of Excellence program, and Burke is the only recipient in New York. Burke, a member of the Montefiore Health System, was cited for adopting rehabilitation technology, training clinicians and delivering patient-centered care.

Burke uses five Bioness systems for at least 30 patients per day

Burke deploys Vector, H200 Wireless, L300 Go Plus, BITS and BITS Balance across its inpatient and outpatient programs. The systems serve patients with neurological and orthopedic conditions, including stroke, spinal cord injury, balance deficits and concussion. The hospital says the tools support at least 30 patients per day working on strength, mobility, balance and upper-extremity function.

Boston – November 05, 2026 -- Haemonetics Corporation (NYSE: HAE) has published its second-quarter fiscal 2027 results for the period that ended September 26, 2026, and will discuss them with investors and analysts on a call at 8:00 a.m. ET on November 5, 2026.

Haemonetics posts earnings release and supplemental presentation online

The company placed two documents on its Investor Relations website: the Second Quarter Fiscal 2027 Earnings Release and the Second Quarter Fiscal 2027 Supplemental Earnings Presentation. Management will reference both during the call. The announcement does not disclose revenue, earnings or guidance figures, which are contained in the posted materials.

Long Beach, Calif. – September 18, 2026 -- The Children's Heart Institute at Miller Children's & Women's Hospital has completed two procedures using the Renata Minima Stent, the first FDA-approved stent system engineered specifically for neonates and infants weighing at least 1.5 kg (3.3 pounds) with pulmonary artery stenosis or coarctation of the aorta.

New stent expands with the patient, reducing repeat surgeries

Aubonne – September 17, 2026 -- Intuitive has secured CE mark approval for its da Vinci SP surgical system to perform transvaginal gynecologic procedures, marking the first such indication for the Single Port platform anywhere in the world.

Approval widens da Vinci SP's European surgical scope beyond five existing categories

The new indication adds to da Vinci SP's current CE-marked applications in Europe, which cover endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, and breast procedures. The system now supports natural orifice surgery across transoral, transanal, and transvaginal routes.

Boston – September 17, 2026 -- PerZeption Inc. has secured a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute to fund development of a new photostress recovery test for age-related macular degeneration (AMD), a condition affecting an estimated 20 million people in the United States.

NEI Funds Photostress Recovery Test for Earlier AMD Detection

The award backs the project "Efficient Achromatic and Chromatic Photostress Recovery Assessment for Age-related Macular Degeneration," which will be carried out in collaboration with researchers at the Brunson Center for Translational Vision Research at the University of California, Irvine. The work targets how quickly vision recovers after bright-light exposure, a marker of macular health that can reveal functional deficits before they show up on standard acuity tests.

Cordova, Tenn. – September 17, 2026 -- Aesthetic Management Partners (AMP) has added ATTIVA®, an intelligent subdermal radiofrequency platform developed by Italy's Tema Medicina S.R.L., to its aesthetic technology portfolio, the company announced.

ATTIVA delivers controlled thermal energy beneath the skin to remodel tissue

The platform uses a fine, insulated cannula to deliver radiofrequency energy into subdermal tissue, producing immediate collagen contraction while supporting progressive collagen and elastin regeneration. It targets the face, neck, jawline, submental area and body, and is designed as a minimally invasive option with limited downtime for most patients.

Madison, Wis. – September 17, 2026 -- Accuray Incorporated (NASDAQ: ARAY) and RaySearch Laboratories AB (publ) have signed a definitive agreement expanding their collaboration to accelerate adoption of online adaptive radiation therapy, with Accuray committing to purchase RayStation software licenses valued at $8 million.

Accuray commits $8 million to RaySearch software licenses

Under the deal, Accuray will buy specified RayStation licenses to support commercialization of online adaptive radiation therapy solutions, which both companies will jointly market and support. The agreement also brings RaySearch's RayCare technology into the partnership to simplify connectivity between clinical systems and streamline adaptive workflows.

Toronto – September 17, 2026 -- iGan Partners, a Toronto-based venture capital firm focused on medical device, diagnostic, imaging, and digital health companies, disclosed a series of portfolio milestones, headlined by a development contract worth up to $70 million awarded to portfolio company Flosonics Medical.

Flosonics secures BARDA contract to extend ultrasound tech into trauma care

The contract, from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services, includes approximately $15 million in initial funding. It supports FloPredict, an AI-enabled software enhancement to Flosonics' FDA-cleared FloPatch device, expanding the real-time ultrasound technology into trauma care and mass casualty response applications.

Oklahoma City – September 17, 2026 -- Acarix AB announced that a peer-reviewed study published in PLOS Digital Health found its seismocardiography (SCG) technology can detect heart failure with diagnostic accuracy comparable to NT-proBNP, the current standard blood test, while producing significantly fewer false positives.

SCG algorithm matches blood test accuracy with far higher specificity

Researchers at Aalborg University Hospital, Aarhus University Hospital and Odense University Hospital enrolled 218 patients, including 198 referred by general practitioners for suspected heart failure and 20 with previously confirmed HFrEF. Using machine learning, the team built two SCG-based scores: an 'AnyHF-score' to flag heart failure of any type, and an 'HFrEF-score' targeting the more severe reduced-ejection-fraction form of the condition.

New York – September 16, 2026 -- NYU Langone Health's Perlmutter Cancer Center has named Sean L. Berry, PhD, vice chair of physics and dosimetry in its Department of Radiation Oncology, recruiting a 20-year veteran of Memorial Sloan Kettering Cancer Center to lead treatment-planning quality and safety programs.

Berry moves from a regional physicist role overseeing multi-site radiation oncology operations

Before joining NYU Langone, Berry served as regional lead physicist and associate attending physicist at Memorial Sloan Kettering Cancer Center, managing clinical physics operations across outpatient sites in Westchester County, New York, and Bergen County, New Jersey. His duties included supervising faculty physicists, staff physicists and dosimetrists, regulatory readiness, accreditation activities, budget oversight, linear accelerator commissioning and standardizing radiation oncology practice across multiple locations.